<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02622880</url>
  </required_header>
  <id_info>
    <org_study_id>VEGENAT</org_study_id>
    <nct_id>NCT02622880</nct_id>
  </id_info>
  <brief_title>Comparison of Two Immunomodulatory Formulas on the Number of Postoperative Infections in Head &amp; Neck Cancer Patients</brief_title>
  <official_title>Comparison of Two Immunomodulatory Formulas on the Number of Postoperative Infections in Oropharyngeal and Maxillofacial Cancer Patients Eligible Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Investigación Hospital Universitario La Paz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vegenat, S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto de Investigación Hospital Universitario La Paz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of an immune formula , consumed 10 days&#xD;
      before surgery , on the number and characteristics of postoperative infections for a period&#xD;
      of 30 days in a group of oropharynx, hypopharynx , larynx and oral cavity squamous cell&#xD;
      cancer patients, candidates for surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      68 subjects randomized into two study groups: 34 subjects consume the supplement of the study&#xD;
      and 34 control consume the supplement IMPACT.&#xD;
&#xD;
      Intervention period will be 10 days before surgery . The consume amount is 400 ml/ day. The&#xD;
      Subjects were stratified according to tumor location ( larynx and oral cavity and oropharynx,&#xD;
      hypopharynx) and disease stage (early and advanced).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of postoperative infections</measure>
    <time_frame>30 days after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Retinol-binding protein</measure>
    <time_frame>0 and 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of post-operative hospital stay</measure>
    <time_frame>through study completion, an average of 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>through study completion, an average of 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline C-reactive protein</measure>
    <time_frame>0 and 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline albumin</measure>
    <time_frame>0 and 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline transferrin</measure>
    <time_frame>0 and 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline prealbumin</measure>
    <time_frame>0 and 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline Bioelectrical impedance analysis</measure>
    <time_frame>0 and 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline leukocytes</measure>
    <time_frame>0 and 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline Fibrinogen</measure>
    <time_frame>0 and 30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Head and Neck Neoplasms</condition>
  <arm_group>
    <arm_group_label>: IMPACT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>along 10 days before surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>immunomodulatory supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>along 10 days before surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>immunomodulatory supplement</intervention_name>
    <description>Experimental Group (immunomodulatory supplement STUDY)</description>
    <arm_group_label>immunomodulatory supplement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>IMPACT</intervention_name>
    <description>IMPACT (Nestle Healthcare Nutrition, Minnesota USA) an 'immune-enhancing' feed which contains supplemental L-arginine (1.25 78 g/L), dietary nucleotides (1.2 g/L) and omega-3 fatty acids in the form of 79 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (EPA/DHA 1.7 g/L) 80 as its active ingredients.</description>
    <arm_group_label>: IMPACT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women &gt;18 years&#xD;
&#xD;
          -  Patients with histologically confirmed squamous cell cancer of the oropharynx,&#xD;
             hypopharynx , larynx and oral cavity and candidates for neoplastic surgery (undergoing&#xD;
             surgery)&#xD;
&#xD;
          -  Adequate cultural level and understanding for the clinical trial. and agree to&#xD;
             participate voluntarily in the study and give written informed consent&#xD;
&#xD;
          -  Patients who do not participate in other clinical trials&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with an active infectious process at the time of the study.&#xD;
&#xD;
          -  Patients who have undergone radiotherapy / chemotherapy prior to surgery.&#xD;
&#xD;
          -  Subjects diagnosed with Type I Diabetes Mellitus&#xD;
&#xD;
          -  Subjects who used oral hypoglycemic agents or insulin.&#xD;
&#xD;
          -  Patients with severe kidney disease, heart, respiratory or liver.&#xD;
&#xD;
          -  Patients with autoimmune diseases or immunosuppressive drugs used.&#xD;
&#xD;
          -  Subjects with dementia, mental illness or diminished cognitive function.&#xD;
&#xD;
          -  Subjects who refuse oral supplements.&#xD;
&#xD;
          -  Subjects who consume vitamin supplements or artificial nutrition, and which can not be&#xD;
             suspended at least 1 week before the study and do not accept to suspend it during the&#xD;
             study.&#xD;
&#xD;
          -  Subjects with morbid obesity (BMI ≥ 40 kg / m2).&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Patients diagnosed with epidermoid carcinoma T1 glottic, cordectomy candidate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carmen Gomez Candela</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario La Paz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitairo La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>November 24, 2015</study_first_submitted>
  <study_first_submitted_qc>December 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2015</study_first_posted>
  <last_update_submitted>December 2, 2015</last_update_submitted>
  <last_update_submitted_qc>December 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

